Regulus Therapeutics Inc (RGLS)
2.65
-0.04
(-1.49%)
USD |
NASDAQ |
May 03, 16:00
2.65
0.00 (0.00%)
After-Hours: 20:00
Regulus Therapeutics Cash from Investing (Quarterly): 4.932M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.932M |
| September 30, 2023 | -5.44M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 15.00M |
| December 31, 2022 | 10.47M |
| September 30, 2022 | -12.86M |
| June 30, 2022 | -12.62M |
| March 31, 2022 | -0.102M |
| December 31, 2021 | -0.041M |
| September 30, 2021 | -0.026M |
| June 30, 2021 | -0.131M |
| March 31, 2021 | -0.053M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | -0.011M |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -0.059M |
| September 30, 2019 | -0.141M |
| June 30, 2019 | 0.113M |
| March 31, 2019 | 0.161M |
| December 31, 2018 | 6.44M |
| September 30, 2018 | 12.93M |
| June 30, 2018 | 15.71M |
| March 31, 2018 | 11.44M |
| Date | Value |
|---|---|
| December 31, 2017 | 4.398M |
| September 30, 2017 | -23.80M |
| June 30, 2017 | 14.98M |
| March 31, 2017 | 18.36M |
| December 31, 2016 | 15.38M |
| September 30, 2016 | 2.936M |
| June 30, 2016 | 5.30M |
| March 31, 2016 | 11.69M |
| December 31, 2015 | 13.04M |
| September 30, 2015 | 5.499M |
| June 30, 2015 | 10.32M |
| March 31, 2015 | -7.39M |
| December 31, 2014 | -38.84M |
| September 30, 2014 | 8.579M |
| June 30, 2014 | 11.54M |
| March 31, 2014 | -10.48M |
| December 31, 2013 | -6.365M |
| September 30, 2013 | -27.50M |
| June 30, 2013 | 8.72M |
| March 31, 2013 | -15.75M |
| December 31, 2012 | -44.74M |
| September 30, 2012 | 8.512M |
| June 30, 2012 | -0.281M |
| March 31, 2012 | 6.123M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-12.86M
Minimum
Sep 2022
15.00M
Maximum
Mar 2023
-0.0515M
Average
-0.026M
Median
Sep 2021
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | -0.347M |
| ADMA Biologics Inc | -1.407M |
| FibroGen Inc | 10.24M |
| Protara Therapeutics Inc | 14.52M |
| Amylyx Pharmaceuticals Inc | 20.92M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.125M |
| Cash from Financing (Quarterly) | -0.873M |
| Free Cash Flow | -27.38M |
| Free Cash Flow Per Share (Quarterly) | -0.3062 |
| Free Cash Flow Yield | -54.52% |